Home > Rheumatology > EULAR 2020 > Ankylosing Spondylitis > AxSpA real-life remission rates higher on biologics

AxSpA real-life remission rates higher on biologics

Presented By
Dr Charlotte Baert, Saint Luc University Hospital, Belgium
Conference
EULAR 2020
Randomised controlled trials have shown that remission occurs infrequently in axial spondyloarthritis (axSpA) patients treated without biologics [1,2]. Yet, data on remission rates in daily clinical practice are scarce. Thus, Dr Charlotte Baert (Saint Luc University Hospital, Belgium) and colleagues aimed to assess the remission rate in axSpA patients in real life, and to compare the remission rate in axSpA patients on non-steroidal anti-inflammatory drugs (NSAIDs) to the remission rate of those on biologic agents (i.e. tumour necrosis factor [TNF]α blockers or interleukin [IL]-17A blockers) [3]. This was a cross-sectional study that reviewed clinical data from a single centre (UCLouvain, Belgium) between January 2013 and March 2019, and the last visit available for clinical assessment was evaluated. The analysis included data from 551 axSpA patients of whom 64.3% were male. Disease activity was measured using the Bath Ankylosing Spondylitis Disease Activi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on